UNITED STATES SECURITIES AND EXCHANGE
COMMISSION Washington, D.C. 20549  FORM 10-Q   [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934  For the quarterly
period ended March 31, 2008   [   ] TRANSITION REPORT UNDER SECTION 13 OR
15(d) OF THE EXCHANGE ACT  For the transition
period from __________ to __________  Commission File
Number 000-24480  Sanguine Corporation (Exact name of registrant as specified in
its charter)  Nevada 95-4347608 (State or
other jurisdiction of (IRS Employer Identification No.) incorporation or organization)  101
East Green Street, #6, Pasadena, California 91105 (Address of principal executive
offices)  (Zip Code)  (626) 405-0079 (Registrants telephone number,
including area code)  Indicate by check mark whether the
registrant (1) has filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes [X]   No [   ]  Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company.  See definitions of large
accelerated filer, accelerated filer, and smaller reporting company in Rule
12b-2 of the Exchange Act.  Large
Accelerated filer  ̈ Accelerated filer  ̈ Non-accelerated
filer   ̈ (Do not check if a
smaller reporting company) Smaller reporting company x  Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ]
  No [X]  Indicate the number of shares outstanding of each of the
issuers classes of common equity, as of the latest practicable date. 103,284,492 shares of $0.001 par value
common stock on April 29, 2008    Part I -
FINANCIAL INFORMATION  Item 1. Financial Statements Sanguine Corporation FINANCIAL STATEMENTS (UNAUDITED) March 31, 2008  The financial statements
included herein have been prepared by the Company, without audit, pursuant to
the rules and regulations of the Securities and Exchange Commission.
 Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted.  However, in the opinion of
management, all adjustments (which include only normal recurring accruals)
necessary to present fairly the financial position and results of operations for
the periods presented have been made.  These financial statements should be
read in conjunction with the accompanying notes, and with the historical
financial information of the Company.     SANGUINE CORPORATION & SUBSIDIARY (A
Development Stage Company) Consolidated Balance Sheets   ASSETS    March 31,
2008

December 31,
2007(Unaudited)CURRENT
ASSETSCash
$
199,724
$
15,436Prepaid
expenses

502,167

770,384Total
Current Assets

701,891

785,820PROPERTY AND
EQUIPMENT, NET

596

670OTHER
ASSETSLong term
prepaid expenses

81,000

111,375TOTAL
ASSETS
$
783,487
$
897,865                         The
accompanying notes are an integral part of these consolidated financial
statements.      SANGUINE CORPORATION & SUBSIDIARY (A
Development Stage Company) Consolidated Balance Sheets (Continued)   LIABILITIES AND SHAREHOLDERS EQUITY    March 31,
2008

December 31,
2007(Unaudited)CURRENT
LIABILITIESAccounts
payable
$
338,473
$
332,719Related party
payable

6,956

-Accrued
compensation

46,063

39,938Total
Current Liabilities

391,492

372,657COMMITMENTS AND
CONTINGENCIESSHAREHOLDERS
EQUITYCommon stock,
200,000,000 shares authorized   of $0.001 par value, 97,767,825
shares
issued
and outstanding

97,768

97,768Additional paid
in capital

7,719,119

7,719,119Common stock
subscription

280,000

-Deficit
accumulated during the development stage

(7,704,892)

(7,291,679)Total
Shareholders Equity

391,995

525,208TOTAL
LIABILITIES AND SHAREHOLDERS
EQUITY
$
783,487
$
897,865             The
accompanying notes are an integral part of these consolidated financial
statements.


SANGUINE CORPORATION & SUBSIDIARY (A
Development Stage Company) Consolidated Statements of Operations (Unaudited) For the Three Months Ended
March 31,

From Inception of the Development
Stage on January 18, 1990 through March 312008

2007

2008REVENUES
$
-
$
-
$
191,762OPERATING
EXPENSESProfessional
fees

380,942

21,105

4,027,041Research
and development

-

72,183

1,973,158Selling,
general and administrative

24,090

11,922

2,726,359Total
Operating Expenses

405,032

105,210

8,726,558LOSS FROM
OPERATIONS

(405,032)

(105,210)

(8,534,796)OTHER INCOME
(EXPENSE)Interest
income

429

42

39,934Interest
expense

-

-

(667,986)Loss
on foreign currency exchange

(8,610)

-

(28,931)Loss
on cash deposit

-

-

(10,020)Gain
on settlement of debt

-

-

1,496,907Total
Other Income (Expense)

(8,181)

42

829,904NET INCOME
(LOSS)

(413,213)

(105,168)

(7,704,892)OTHER
COMPREHENSIVE INCOME (LOSS)Loss
on foreign currency exchange

-

(1,592)

-TOTAL
COMPREHENSIVE INCOME (LOSS)
$
(413,213)
$
(106,760)
$
(7,704,892)BASIC INCOME
(LOSS) PER SHARE
$
(0.00)
$
(0.00)DILUTED INCOME
PER SHARE
$
(0.00)
$
(0.00)WEIGHTED
AVERAGE NUMBER OF SHARES OUTSTANDING BASIC AND DILUTED

97,767,825

81,236,834  The
accompanying notes are an integral part of these consolidated financial
statements.      SANGUINE CORPORATION & SUBSIDIARY (A Development Stage Company) Consolidated Statements of Cash
Flows (Unaudited) For the Three Months Ended
March 31,

From Inception of the Development Stage on January 18, 1990
through March 312008

2007

2008Net
loss
$
(413,213)
$
(105,168)
$
(7,704,892)Adjustments to
reconcile net loss to net cash used
by
operating activities:Depreciation
and amortization

74

74

5,504Common
stock issued for services

-

61,188

3,330,446Contributed
capital

-

-

520Stock
warrants granted

-

-

8,650Interest
on beneficial conversion feature

-

-

25,000Legal
expense related to beneficial conversion feature

-

-

3,750Note
payable issued for services

-

-

727,950Gain
on extinguishments of debt

-

-

(98,826)Gain
on conversions of debt to equity

-

-

(1,398,081)Recognition
of prepaid expenses and

expenses
prepaid with common stock

-

-

456,184Warrant
extension

-

-

34,493Loss
on Foreign currency exchange

8,610

-

28,931Changes
in assets and liabilities:(Increase)
decrease in prepaid expense

298,592

-

266,816Increase
in accounts payable and related party payables

4,100

(22,885)

644,686Increase
in accrued interest payable

-

-

547,279Increase
in accrued liabilities

-

-

10,125Increase
in customer deposits`

-

-

45,000Increase
(decrease) in warrant liability

-

1,131

-Increase
in accrued salaries

6,125

(61,749)

941,125Net
Cash Used by Operating Activities

(95,712)

(127,409)

(2,125,340)CASH FLOWS FROM
INVESTING ACTIVITIESCash
paid for fixed assets

-

-

(6,100)Net
Cash Used by Investing Activities

-

-

(6,100)CASH FLOWS FROM
FINANCING ACTIVITIESProceeds
from warrant conversion

-

100,000

524,700Proceeds
from notes payable and notes payable-

related
party

-

-

214,139Payments
on notes payable and notes payable 

related
party

-

-

(15,400)Proceeds
from issuance of convertible debentures

-

-

40,000Contributed
capital

-

-

750Common
stock subscription

280,000

-

280,000Common
stock issued for cash

-

16,999

1,286,975Net
Cash Provided by Financing Activities

280,000

116,999

2,331,164NET INCREASE
(DECREASE) IN CASH

184,288

(10,410)

199,724CASH
AT BEGINNING OF PERIOD

15,436

30,288

-CASH AT END OF
PERIOD
$
199,724
$
19,878
$
199,724  The
accompanying notes are an integral part of these consolidated financial
statements.      SANGUINE CORPORATION & SUBSIDIARY (A
Development Stage Company) Consolidated Statements of Cash Flows(Continued) (Unaudited)    For the Three Months Ended
March 31,

From Inception of the Development
Stage on January 18, 1990 through March 312008

2007

2008  SUPPLEMENTAL SCHEDULE OF CASH FLOW
ACTIVITIESCASH PAID FOR:Interest
$
-
$
-
$
-Income taxes
$
-
$
-
$
-NON-CASH FINANCING ACTIVITIESCommon stock issued for debt
conversion
$
-
$
-
$
9,600Equity instruments issued for services
rendered
$
-
$
61,188
$
3,186,634Contributed capital for interest
contributed
$
-
$
-
$
520Interest on beneficial conversion
feature
$
-
$
-
$
25,000Legal related to beneficial conversion
feature
$
-
$
-
$
3,750Notes payable issued for
services
$
-
$
-
$
727,950Common stock issued for prepaid
services
$
-
$
-
$
236,284Common stock issued for debt
$
-
$
-
$
2,822,067               The accompanying notes are
an integral part of these consolidated financial statements.       SANGUINE CORPORATION & SUBSIDIARY (A
Development Stage Company) Notes to
Consolidated Financial Statements March
31, 2008 and December 31, 2007   NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION  The accompanying unaudited financial statements have been prepared
by the Company pursuant to the rules and regulations of the Securities and
Exchange Commission.  Certain information and footnote disclosures normally
included in financial statements prepared in accordance with accounting
principles generally accepted in the United States of America have been
condensed or omitted in accordance with such rules and regulations.  The
information furnished in the interim financial statements includes normal
recurring adjustments and reflects all adjustments, which, in the opinion of
management, are necessary for a fair presentation of such financial statements.
 Although management believes the disclosures and information presented are
adequate to make the information not misleading, it is suggested that these
interim financial statements be read in conjunction with the Companys most
recent audited financial statements and notes thereto included in its December
31, 2007 Annual Report on Form 10-KSB.  Operating results for the three
months ended March 31, 2008 are not necessarily indicative of the results that
may be expected for the year ending December 31, 2008.  NOTE 2 - ORGANIZATION AND DESCRIPTION OF BUSINESS  Sanguine Corporation, (the Company) was incorporated January 27,
1974, in the State of Utah, using the name Sight and Sound Systems, Inc.
 On July 8, 1974, the Company changed its name to International Health
Resorts, Inc., and on June 25, 1993, the Company filed a Certificate of
Amendment changing the name to Sanguine Corporation.  In May of 1992, the
Company changed its domicile to the State of Nevada.  The Company is engaged in developing oxygen carriers to be used by
the medical profession.  The Company is conducting research and development
leading to F.D.A. clinical trials.  On June 14, 1993, the Company entered into an Agreement and Plan
of Reorganization, wherein it was agreed that Sanguine Corporation (a Nevada
Corporation) would issue 14,589,775 shares of its common stock to acquire 94% of
the issued and outstanding shares of stock of Sanguine Corporation (a California
Corporation).  During the year ended December 31, 2001, the Company
acquired the remaining 6% of the California Corporation in exchange for the
issuance of 840,195 shares of common stock.  From 1974 to 1980, the Company engaged in several business
ventures.  These business activities resulted in the loss of all Company
assets.  Because of the search for a new business venture, the Company has
entered into the development stage company status again.  The Company is
a development stage company and these financial statements are presented as
those of a development stage company effective January 18, 1990, coinciding with
the incorporation date of Sanguine Corporation.  On March 7, 2008, the Company formed a wholly owned subsidiary
called Sanguine Lifescience Corporation.  As part of the formation of
Sanguine Lifescience Corporation, the Company transferred $15,000 to a bank
account for Sanguine Lifescience use.  At this time, Sanguine Lifescience
Corporation is not engaged in any business other than normal corporate
matters.       SANGUINE CORPORATION & SUBSIDIARY (A
Development Stage Company) Notes to
Consolidated Financial Statements March 31, 2008 and December 31, 2007  NOTE 3 - GOING CONCERN  The Companys financial statements are prepared using accounting
principles generally accepted in the United States of America applicable to a
going concern which contemplates the realization of assets and liquidation of
liabilities in the normal course of business.  The Company has not yet
established an ongoing source of revenues sufficient to cover its operating
costs and allow it to continue as a going concern.  The ability of the
Company to continue as a going concern is dependent on the Company obtaining
adequate capital to fund operating losses until it becomes profitable.  If
the Company is unable to obtain adequate capital, it could be forced to cease
operations.  The Companys management has taken certain steps to maintain its
operating and financial requirements in an effort to continue as a going concern
until such time as revenues are sufficient to cover expenses.  Future plans
include a debt or equity offering for between $1,000,000 - $1,500,000 that
should enable the Company to complete the animal testing stage for FDA approval
of its product.  However, management cannot provide any assurance that the
Company will be successful in accomplishing any of its plans.  The ability of the Company to continue as a going concern is
dependent upon its ability to successfully accomplish the plans described in the
preceding paragraph and eventually secure other sources of financing and attain
profitable operations.  The accompanying financial statements do not
include any adjustments that might be necessary if the Company is unable to
continue as a going concern.  NOTE 4 - STOCK WARRANTS AND OPTIONS  A summary of the status of the Companys outstanding stock
warrants as of March 31, 2008 and December 31, 2007 and changes during the
periods then ended is presented below:  2008

2007Shares

Weighted Average Exercise Price

Shares

Weighted Average Exercise
PriceOutstanding, beginning of year
723,115

$
0.08

2,213,115

$
0.08Granted
-


-

-


-Expired/Cancelled
(723,115)


0.08

(150,000)


0.125Exercised
-


-

(1,250,000)


0.08Outstanding end of year
-

$
-

723,115

$
0.08Exercisable
-

$
-

723,115

$
0.08        SANGUINE CORPORATION & SUBSIDIARY (A
Development Stage Company) Notes to
Consolidated Financial Statements March 31, 2008 and December 31, 2007  NOTE 4 - STOCK WARRANTS AND OPTIONS (continued)   A summary of the status of the Companys outstanding stock options
as of March 31, 2008 and December 31, 2007 and changes during the periods then
ended is presented below:   2008

2007Shares

Weighted Average Exercise Price

Shares

Weighted Average Exercise
PriceOutstanding, beginning of year
5,000,000

$
0.06

-

$
-Granted
-


-

5,000,000


0.06Expired/Cancelled
-


-

-


-Exercised
-


-

-


-Outstanding end of year
5,000,000

$
0.06

5,000,000

$
0.06Exercisable
5,000,000

$
0.06

5,000,000

$
0.06  Outstanding

ExercisableRange of Exercise Prices

Number outstanding at March 31,
2008

Weighted Average Remaining Contractual
Life

Number Exercisable at March
31,2008$
0.06

5,000,000

1.00

5,000,0005,000,000



5,000,000  NOTE 5 - RELATED PARTY TRANSACTION  Related party payables at March 31, 2008 represent amounts owed to
officers of the Company for consulting fees and reimbursement of expenses paid
of $6,956.  NOTE 6 - SUBSEQUENT EVENTS  Subsequent to quarter end the Company issued 4,666,667 shares of
common stock valued at $280,000 for subscriptions received.  The Company
has retained an investor relation firm which will be paid $20,000 and issued
500,000 shares of our common stock.  The term of the agreement is for one
year.  The Company also issued 350,000 shares in payment of previously
accrued compensation.        Item 2. Managements Discussion and Analysis of
Financial Condition and Results of Operations  Special Note Regarding Forward-Looking
Statements  This periodic report contains certain
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 with respect to the Plan of Operations provided
below, including information regarding the Companys financial condition,
results of operations, business strategies, operating efficiencies or synergies,
competitive positions, growth opportunities, and the plans and objectives of
management. The statements made as part of the Plan of Operations that are not
historical facts are hereby identified as "forward-looking statements." Critical Accounting Policies
and Estimates  The preparation of financial statements and
related disclosures in conformity with accounting principles generally accepted
in the United States of America requires management to make estimates and
assumptions that affect the amounts reported in the unaudited Financial
Statements and accompanying notes.  Management bases its estimates on
historical experience and on various other assumptions that are believed to be
reasonable under the circumstances. Actual results could differ from these
estimates under different assumptions or conditions.  The Company
believes there have been no significant changes during the three month
periods ended March 31, 2008 and 2007, to the items disclosed as
significant accounting policies since the Companys last audited financial
statements for the year ended December 31, 2007.  The Companys accounting policies are more
fully described in Note 1 of the consolidated financial statements.  As
discussed in Note 1, the preparation of financial statements and related
disclosures in conformity with accounting principles generally accepted in the
United States of America requires management to make estimates and assumptions
about the future events that affect the amounts reported in the consolidated
financial statements and the accompanying notes. Management bases its estimates
on historical experience and on various other assumptions that are believed to
be reasonable under the circumstances.  Actual differences could differ
from these estimates under different assumptions or conditions.  The
Company believes that the following addresses the Companys most critical
accounting policies.  We recognize revenue in accordance with
Securities and Exchange Commission Staff Accounting Bulletin No. 104, Revenue
Recognition (SAB 104).  Under SAB 104, revenue is recognized at the
point of passage to the customer of title and risk of loss, when there is
persuasive evidence of an arrangement, the sales price is determinable, and
collection of the resulting receivable is reasonably assured.  We recognize
revenue as services are provided.  Revenues are reflected net of coupon
discounts.  We account for income taxes in accordance
with Statement of Financial Accounting Standards No. 109, Accounting for Income
Taxes (SFAS No. 109).  Under SFAS No. 109, deferred tax assets and
liabilities are measured using enacted tax rates in effect for the year in which
the differences are expected to reverse.  Deferred tax assets will be
reflected on the balance sheet when it is determined that it is more likely than
not that the asset will be realized.  A valuation allowance has currently
been recorded to reduce our deferred tax asset to $0.  Plan of Operation.  We have not commenced planned principal
operations, but have made progress, in formulation and stability testing.  In January, 2005, we were successful in
developing improved formulations of our surfactants for PHER-02.  In December, 2006, we completed a pre-IND
meeting with the FDA, where Company management presented data to determine an
appropriate regulatory path related to PHER-O2.  Pending additional funding our plan of
operation for the next 12 months is to complete the preparation and submission
of the U.S. FDA New Device Application to support PHER-02 as a synthetic oxygen
carrying product.  Our proposed plan of operation is composed
of "stages," each of which coincides with a specific milestone in the process of
developing PHER-O2. Each stage, and the projected cost of each, is as
follows:  Stage A (approximately three-six months):
Complete the development of perfluoro-decalin and the synthetic
 surfactants that make up PHER-O2, manufactured experimental doses in
accordance with FDA and overseas regulations and submit data to support a Master
Drug Filing.  Estimated cost is not to exceed $500,000, divided as follows:
Completed surfactant formulation (done) and the manufacture of      sufficient
product for testing, (on going); animal safety and efficacy trials through a
sub-contractor, (done); and administrative, patent and proprietary right
protection and marketing costs,(in process) Optimize stabilized product to
support the Master Drug Filing (in process).  Stage B (approximately three-six months):
In the second period, we will produce optimal quantities and conduct testing in
accordance with FDA and overseas requirements.  During the course of Stage
A, we estimate that our increased technical, administrative, sales/marketing and
manufacturing requirements will require us to the hire a few additional
contractors and/or employees.  Stage C (approximately three-six months):
In the third period, we intend to prepare new 510(k) device application with the
FDA.  Estimated cost is $1,000,000, to be used as follows: set-up pilot
facility, or subcontractor, to manufacture small quantities of PHER-O2 for use
in testing and in connection with the New Drug Applications [done], prepare and
submit data for use of PHER-O2 as a whole organ transportation medium in support
of FDA labeling, and administrative, patent and proprietary right protection and
marketing costs, (in process).  These cost estimates are based upon the
prior experience of Thomas C. Drees, Ph.D., our President and CEO.  Dr.
Drees has more than 33 years' experience in the blood industry with Abbott
Scientific, Alpha Therapeutics and Sanguine Corporation.  Results of Operations  Three Months Ended March 31, 2008,
Compared to the Three Months Ended March 31, 2007  The Company continues to not have revenues
as it focuses on the development of its products.  As such, the Company has
not had revenue in either the quarter ended March 31, 2008 or 2007.  We had
no material operations, except the research and development activities related
to our subcontracted research and development of our product, PHER-O2.  We realized a net loss of $413,213 for the
quarter ended March 31, 2008, and a net loss of $105,168 for the quarter ended
March 31, 2007.  Most of our expense related to professional fees for the
quarter ended March 31, 2008. Professional fees increased as a result of the
amortization of prepaid expenses related to consulting agreements entered into
during the prior year.  We anticipate professional fees to not be as high
in upcoming quarters.  With the focus the last three months on
raising capital and evaluating our business model, our research and development
expenses were $0 for the quarter ended March 31, 2008, compared to $72,183 in
the same period of 2007.  Subsequent to the quarter ended March 31,
2008, we sold 4,666,667 shares of stock for $280,000.  Liquidity and Capital Resources  As of March 31, 2008, we had $199,724 in
cash and $502,167 in prepaid expenses, with $391,492 in current liabilities.
 Although we had a working capital of $310,399 at March 31, 2008, our cash
position is not sufficient to cover our accounts payable  or other current
liabilities.  As such we will be dependent on our ability to raise
additional debt or equity capital to be able to cover current liabilities.
 Subsequent to the quarter ended March 31, 2008, we sold 4,666,667 shares
of common stock in connection with a stock purchase agreement for $280,000.
 Even with the additional capital, we still need additional capital
infusions to cover ongoing expenses and pay existing liabilities.       Off-balance
sheet arrangements  We had no off-balance sheet arrangements during the
quarter ended March 31, 2008.  Off-Balance Sheet Arrangements  We have no off balance sheet arrangements as of March 31,
2008.  Forward-looking Statements  The Private Securities Litigation Reform
Act of 1995 (the Act) provides a safe harbor for forward-looking statements
made by or on behalf of our Company. Our Company and our representatives may
from time to time make written or oral statements that are forward-looking,
including statements contained in this Annual Report and other filings with the
Securities and Exchange Commission and in reports to our Companys stockholders.
Management believes that all statements that express expectations and
projections with respect to future matters, as well as from developments beyond
our Companys control including changes in global economic conditions are
forward-looking statements within the meaning of the Act. These statements are
made on the basis of managements views and assumptions, as of the time the
statements are made, regarding future events and business performance. There can
be no assurance, however, that managements expectations will necessarily come
to pass. Factors that may affect forward- looking statements include a wide
range of factors that could materially affect future developments and
performance, including the following:  Changes in Company-wide strategies, which
may result in changes in the types or mix of businesses in which our Company is
involved or chooses to invest; changes in U.S., global or regional economic
conditions, changes in U.S. and global financial and equity markets, including
significant interest rate fluctuations, which may impede our Companys access
to, or increase the cost of, external financing for our operations and
investments; increased competitive pressures, both domestically and
internationally, legal and regulatory developments, such as regulatory actions
affecting environmental activities, the imposition by foreign countries of trade
restrictions and changes in international tax laws or currency controls; adverse
weather conditions or natural disasters, such as hurricanes and earthquakes,
labor disputes, which may lead to increased costs or disruption of
operations.  This list of factors that may affect future
performance and the accuracy of forward-looking statements is illustrative, but
by no means exhaustive. Accordingly, all forward-looking statements should be
evaluated with the understanding of their inherent uncertainty.  Item 3.  Quantitative and Qualitative Disclosures
About Market Risk.  NA-Small Reporting Company  Item 4T.  Controls and Procedures.  Evaluation of Disclosure Controls and
Procedures  Our
management, with the participation of our President and CFO, evaluated the
effectiveness of our disclosure controls and procedures as of the end of the
period covered by this report. Based on that evaluation, our President and CFO
concluded that our disclosure controls and procedures as of the end of the
period covered by this report were effective such that the information required
to be disclosed by us in reports filed under the Exchange Act is
(i) recorded, processed, summarized and reported within the time periods
specified in the SECs rules and forms and (ii) accumulated and
communicated to our management, including our President and CFO, as appropriate
to allow timely decisions regarding disclosure. A controls system cannot provide
absolute assurance, however, that the objectives of the controls system are met,
and no evaluation of controls can provide absolute assurance that all control
issues and instances of fraud, if any, within a company have been detected.        Managements Report on Internal Control
over Financial Reporting  Our
management is responsible for establishing and maintaining adequate internal
control over financial reporting (as defined in Rule 13a-15(f) under the
Exchange Act). Our internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes of
accounting principles generally accepted in the United States.   Because of its inherent limitations, internal
control over financial reporting may not prevent or detect misstatements.
Therefore, even those systems determined to be effective can provide only
reasonable assurance of achieving their control objectives.   Our
management, with the participation of the President and CFO, evaluated the
effectiveness of our internal control over financial reporting as of March 31,
2008.  Based on this evaluation, our management, with the participation of
the President and CFO, concluded that, as of March 31, 2008, our internal
control over financial reporting was effective.  Changes in internal control over
financial reporting  There have been no changes in internal control over
financial reporting.  PART II - OTHER INFORMATION  ITEM 1.  Legal Proceedings   None  ITEM 2.  Unregistered Sales of Equity Securities
and Use of Proceeds  Recent Sales of Unregistered
Securities  We have not sold any restricted securities
during the three months ended March 31, 2008.  However, subsequent to our
quarter end, we issued shares to our medical advisory board members and to our
directors.  These shares reflect our annual accrual of shares we issue to
our medical advisory board and directors with each member receiving 12,500
shares per quarter for 50,000 shares per year.   Our three directors
received an aggregate of 150,000 shares and our four medical advisory board
members received an aggregate of 200,000 shares.  The cost of such shares
are accrued each quarter during the year.  Additionally, subsequent to our
quarter end, Subsequent to our quarter end, we sold 4,666,667 shares of our
common stock to accredited investors in a private placement.  We also
issued 500,000 shares of common stock to a consultant for ongoing consulting
services.  Use of Proceeds of Registered
Securities  None; not applicable.  Purchases of Equity Securities by
Us and Affiliated Purchasers  During the three months ended March 31, 2008, we have not
purchased any equity securities nor have any officers or directors of the
Company.  ITEM 3.  Defaults Upon Senior Securities  We are not aware of any defaults upon senior
securities.       ITEM 4.  Submission of
Matters to a Vote of Security Holders  No matters were submitted to a vote of security holders
during the quarter ended March 31, 2008.  ITEM 5.  Other Information.  Subsequent to our quarter end, we sold
4,666,667 shares of our common stock to accredited investors in a private
placement.   We also issued 500,000 shares of Common Stock to a
consultant for ongoing services to the Company.  Additionally, subsequent
to our quarter end, we issued shares to our medical advisory board members and
to our directors.  These shares reflect our annual accrual of shares we
issue to our medical advisory board and directors with each member receiving
12,500 shares per quarter for 50,000 shares per year.   Our three
directors received an aggregate of 150,000 shares and our four medical advisory
board members received an aggregate of 200,000 shares.  The cost of such
shares are accrued each quarter during the year.  ITEM 6.  Exhibits  (a) Exhibits.  The following exhibits are filed herewith or are
incorporated by reference to exhibits previously filed.   Exhibit Number
              Description 3.2 Articles of Amendment increasing the
authorized shares-Definitive Information Statement filed 12/23/2005**  3.3 Bylaws-8-K Current Report dated
11/28/2005**  10.1 Cervelle Group  14 Code of Ethics-Form 10KSB for the year
ended December 31, 2002**  31.1 302 Certification of Thomas C. Drees,
Ph.D.  31.2 302 Certification of David E.
Nelson  32 906 Certification  *
   Summaries of all exhibits contained within this Report are
modified in their entirety by reference to these Exhibits.  **
  These documents and related exhibits have been previously filed with
the Securities and Exchange Commission and are incorporated herein by
reference.        SIGNATURES  Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.  Sanguine Corporation (Registrant)     Date: May 13, 2008 By: /s/ Thomas C. Drees Thomas
C. Drees, Ph.D., MBA CEO
and Chairman of the Board
of Directors  Date: May 13, 2008 By: /s/ David E. Nelson David
E. Nelson, CPA CFO
and Director